New Drug Application (NDA) meeting with the FDA, achieving broad alignment on the contents of its NDA for inhaled sedation in mechanically ventilated adult patients. The FDA confirmed that the safety ...

Sedana Medical AB (publ) (STO:SEDANA) shares fell 3.9% to kr138 in the week since its latest annual results. It was an okay result overall, with revenues coming in at kr72m, roughly what analysts had ...

If you want to know who really controls Sedana Medical AB (publ) (STO:SEDANA), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, ...

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the ...

STOCKHOLM, July 7, 2021 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has completed a successful End of phase II meeting with the US Food and Drug ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Sedana ...

STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for approval for the drug candidate Sedaconda ...

STOCKHOLM, April 25, 2024 /PRNewswire/ --Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States.

Sedana Medical AB Annual stock financials by MarketWatch. View the latest SEDANA financial statements, income statements and financial ratios.

STOCKHOLM, Feb. 16, 2022 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first bottles of Sedaconda (isoflurane) have been delivered to customers. The first ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.